Gyre Therapeutics Presents Strong Preclinical Data for Cancer Degrader CG923308, Targets Q1 2027 IND

summarizeSummary

Gyre Therapeutics presented strong preclinical data for its cancer drug candidate, CG923308, at a scientific conference, demonstrating its potential in solid tumors and resistant breast cancer, with an IND submission targeted for Q1 2027.

check_boxKey Events

• Scientific Presentation Furnished

  Gyre Therapeutics will present detailed preclinical data for its drug candidate CG923308 at a scientific conference in Shanghai, China on May 15, 2026.

• Strong Preclinical Data for CG923308

  The presentation highlights CG923308, a CDK2-Cyclin E Degrader, showing potent and selective degradation in multiple cancer types and superior anti-cancer efficacy over Phase 2/3 CDK2 inhibitors in preclinical models.

• Targeting Solid Cancers and Resistant Breast Cancer

  CG923308 is being developed for solid tumors with CCNE1 amplification and HR+/HER2- breast cancer resistant to CDK4/6 inhibitors, addressing significant unmet clinical needs.

• IND Submission Anticipated Q1 2027

  Cullgen, a subsidiary of Gyre Therapeutics, anticipates submitting an Investigational New Drug (IND) application for CG923308 in the first quarter of 2027.

auto_awesomeAnalysis

This 8-K furnishes a scientific presentation detailing robust preclinical data for CG923308, a lead asset acquired through the recent Cullgen Inc. acquisition. The data suggests CG923308, a CDK2-Cyclin E Degrader, shows superiority over existing Phase 2/3 CDK2 inhibitors in treating solid cancers and breast cancer resistant to CDK4/6 inhibitors. The announcement of an anticipated Investigational New Drug (IND) application submission in Q1 2027 provides a clear development timeline for this potentially significant therapeutic, validating the strategic value of the Cullgen acquisition.